HomeBUSINESS
BUSINESS

Daiichi Sankyo’s Herceptin Biosimilar Might Hit Market as Early as November, Breast Cancer Use Also Eyed
(Jul.23.2018)

Daiichi Sankyo’s Herceptin (trastuzumab) biosimilar, the company’s first follow-on biologic, might reach the market as early as November for the treatment of not only gastric cancer but also breast cancer, an indication dropped by a leading competitor approved earlier this year ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar